The incidence and clinical significance of antibodies to interferon-α

Interferon Therapy of Multiple Sclerosis

Volumn , Issue , 1997, Pages 509-521

  Öberg, Kjell ^a   McKenna, Rachel M ^b  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^b UNIVERSITY OF MANITOBA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84865929748     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (37)

1. Weissman C, Weber H. The interferon genes. Prog Nucleic Acid Res 1986; 33:251.
2. Gewert D, Salom C, Barber K, et al. Analysis of interferon-α2 sequences in human genomic DNA. J Interferon Res 1993; 13:227.
3. Tillman HL. Different HCV-genotypes and their response to interferon: IX European Interferon Workshop. Hannover, Germany, 1996, p. 40.
4. Hosoi H, Imai M, Yamanaka M. The interferon-α2β gene in Japanese patients with chronic viral hepatitis who developed antibodies after treatment with recombinant interferon-α2a. J. Gastroenterol Hepatol 1992; 7:411.
5. Liao MJ, Lee N, Hussain M, et al. Distribution of IFN-α2 genes in humans (abstr). VIII European Interferon Workshop. Hannover, Germany, 1994.
6. Spiegel RJ. Alpha interferons: a clinical overview. Urology 1989; 34:75.
7. Strander H. Interferon treatment of human neoplasia. In: Klein G, Weinhouse S, eds. Advances in Cancer Research, Vol 46. London: Academic Press, 1986:1-20.
8. Baron S, Tyring SK, Fleischmann WR, et al. The interferons. Mechanisms of actions and clinical applications. JAMA 1991; 266:1375.
9. Stuart-Harris RC, Lauchlan R, Day R. The clinical application of the interferons: a review. Med J Austral 1992; 156:869.
10. Dorr RT. Interferon-alpha in malignant and viral diseases. A review. Drugs 1993; 45:177.
11. Itri LM, Campion M, Dennin RA, et al. Incidence and clinical significance of neutralizing antibodies in patients receiving recombinant alpha-2a by intramuscular injection. Cancer 1987; 59:668.
12. Spiegel RJ, Spicehandler JR, Jacobs SL, et al. Low Incidence of serum neutralizing factors in patients receiving recombinant alpha-2b Interferon (Intron A). Am J Med 1986; 80:223.
13. Figlin RA, Itri LM. Anti-interferon antibodies: a perspective. Semin Hematol 1988; 25:9.
14. Kawade Y. Quantitation of neutralizing of interferon by antibody; Methods Enzymol 1986; 119:558.
15. Protzman WP, Jacobs SL, Minnicozzi M, et al. A radioimmunologic technique to screen for antibodies to α-2 interferon. J Immunol Methods 1984; 75:317.
16. Jacobs SJ, Sullivan LM, Salfi M, et al. Minimal antigenecity of Intron A in human recipients demonstrated by three analytical methods. J Biol Response Modifiers 1988; 7:447.
17. Grossberg SE. Human antibodies to interferons: report of National Institutes of Health Workshop, J Interferon Res 1988; 8:v.
18. Hennes U, Jucker W, Fischer EA, Krummenacher TH, Palleroni AV, Trown PW, et al. The detection of antibodies to recombinant interferon alfa-2a in human serum. J Biol Stand 1987; 15:231.
19. von Wussow P, Pralle H, Jakshies D, et al. Effective treatment of recombinant interferon alpha-2 (IFN-α) antibody-positive hairy cell leukemia (HCL) patients with natural interferon alpha (nIFN) (abstr). Am Soc Hematol 1989.
20. Berman E, Heiler G, Kemoin S, et al. Incidence of response and long-term follow-up in a patient with hairy cell leukemia treated with recombinant interferon alfa-2a. Blood 1990; 75:839.
21. Konrad M, Childs A, Merigan T, et al. Assessment of the antigenic response in humans to a recombinant mutant interferon beta. J Clin Immunol 1987; 7:365-375.
22. Krown SE, Real FX, Einzig AI, et al. Treatment of Kaposi’s sarcoma and renal cell carcinoma with recombinant leukocyte A interferon. In: Kirchner H, Schellekens H, eds. Biol Interferon Systems. Elsevier, 1985:523.
23. Quesada JR, Rios A, Swanson D, et al. Anti tumor activity of recombinantderived interferon alpha in metastatic renal cell carcinoma. J Clin Oncol 1985; 3:1522.
24. Jones GJ, Itri LM. Safety and tolerance of recombinant interferon alfa-2a in cancer patients. Cancer 1986; 57:1709.
25. Grander D, Öberg K, Lundqvist ML, et al. Interferon-enhancement of 2′-5′-oligodenylate synthetase in mid-gut carcinoid tumours. Lancet 1990; 336: 337.
26. Öberg K. Autoimmunity and antibodies to interferons in patients with carcinoid tumors-clinical consequences (abstr). VIII European Interferon Workshop. Hannover, Germany, 1994.
27. von Wussow P, Hehlmann R, Nolte Ku, et al. IFN-α2A (Roferon) is more immunogenic than IFN-α-2B (Intron A) in patients with CML (abstr). VIII European Interferon Workshop. Hannover, Germany, 1994.
28. Breslow NE, Day NE. Classical methods of analysis of grouped data. In: Breslow NE, Day NE, eds. Statistical Methods in Cancer Research. Vol. 1. The Analysis of Case-Control Studies. Lyon: International Agency for Research on Cancer, 1980:122.
29. Antonelli G, Currenti M, Turriziani O, et al. Neutralizing antibodies to interferon-α: relative frequency in patients treated with different interferon preparations. J Infect Dis 1991; 163:882.
30. Steis RG, Smith JW, Urba WJ, et al. Resistance to recombinant interferon alfa-2a hairy cell leukemia associated with neutralizing anti-interferon antibodies. N Engl J Med 1988; 318:1409.
31. von Wussow P, Freund M, Block B, et al. Clinical significance of anti-IFN-α antibody titres during Interferon therapy. Lancet 1987; 2:635.
32. Gutterman JU, et al. The role of interferons in the treatment of hematologic malignancies. Semin Hematol 1988; 25:3.
33. Quesada JR, Itri L, Gutterman JU. Alpha Interferons in hairy cell leukemia (HCL). A five year follow up in 100 patients. J Interferon Res 1987; 7:678.
34. Freund M, von Wussow P, Diedrich H, et al. Recombinant human interferon (IFN) alpha-2b in chronic myelogenous leukemia. Dose dependency of response and frequency of neutralizing anti-interferon antibodies. Br J Hematol 1989; 72:350.
35. Öberg K, Alm G, Magnusson A, et al. Treatment of malignant carcinoid tumors with recombinant interferon alfa-2b: development of neutralizing interferon antibodies and possible loss of anti tumor activity. J Natl Cancer Inst 1989; 81:531.
36. Prtimmer O. Interferon-alpha antibodies in patients with renal cell carcinoma treated with recombinant interferon-alpha-2A in an adjuvant multicenter trial. Cancer 1993; 71:1828.
37. Rönnblom LE, Janson ET, Perers A, et al. Characterization of anti-interferon antibodies appearing during recombinant interferon-α2a treatment. Clin Exp Immunol 1992; 89:330.